An interventional study of Unilateral Resistance Training and Bilateral Resistance Training in Hypertension, sponsored by Hacettepe University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 40 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-07.
Sponsored by Hacettepe University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 128 studies in Hypertension with a site in Turkey — 21 open to participants now, 23 under way, 5 of them phase 3. Hypertension · Turkey.
Among the 128 studies in Hypertension with a site in Turkey, this one is the 72nd largest by planned enrollment of the 93 interventional ones that give a count, is one of 8 that started in 2026, is one of 55 with no phase, reaches primary completion later than 9 of the 22 other live ones, and was the 123rd registered.
6,120 studies on the registry are indexed under Hypertension; 913 are open to participants now.
Browse Hypertension studies →21 of the 128 studies in Hypertension with a site in Turkey are open now. Recruiting first, the newest first:
Hacettepe University · Sites in Turkey
Ages 18+ · Men only
Inonu University · Sites in Turkey
Ages 18+
Kutahya Health Sciences University · Sites in Turkey
Ages 18+ · Healthy volunteers
Nadide Gizem Tarakci Filiz · Sites in Turkey
Ages 40–65
Alnylam Pharmaceuticals · Sites in Turkey, United States, Argentina and 32 more countries
Ages 18+
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 40 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
128 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 27 · Phase 4 9
First in 1998; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 54 is below the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 90 across the 93 interventional studies, 148 across the 35 observational. Of the 103 that completed or were terminated, 22 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 128 have an industry lead sponsor. The 10 most frequent:
Hacettepe University is the lead sponsor of 1,009 studies on the registry; 214 are open to participants now.
Hacettepe University has 5 studies filed under Hypertension — fewer than ten, so there is no comparison to draw.
7 of the studies in Hypertension with a site in Turkey that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT07890090Inonu UniversityTHE EFFECT OF EDUCATION IN PATIENTS WITH HYPERTENSION | 2026-12-01 |
| NCT07222917AstraZenecaA Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure. | 2026-12-10 |
| NCT07189637Nadide Gizem Tarakci FilizThe Combined Effect of the Mediterranean Diet and Intermittent Fasting on Hypertension | 2026-12-15 |
| NCT07747025Kutahya Health Sciences UniversityNurse-Led Motivational Interviewing for Blood Pressure Control | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 128 studies in Hypertension with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Hypertension is associated with autonomic nervous system dysfunction, reduced muscle strength, and impaired functional capacity, all of which contribute to increased cardiovascular risk and decreased quality of life. Resistance training is recommended as a non-pharmacological intervention for hypertension; however, it remains unclear whether unilateral and bilateral resistance training produce different physiological adaptations, particularly regarding cardiac autonomic function.
This randomized controlled trial aims to compare the effects of unilateral and bilateral resistance training on heart rate variability (HRV), muscle strength, and functional capacity in adults with hypertension. Eligible participants aged 40-75 years with a confirmed diagnosis of hypertension will be randomly allocated to one of three groups: a unilateral resistance training group, a bilateral resistance training group, or a control group. Randomization will be performed using a computer-generated block randomization procedure with sex stratification to ensure balanced group allocation.
Participants in the two intervention groups will complete a supervised 12-week resistance training program, performed twice weekly at an intensity of 60-70% of one-repetition maximum (1RM). The unilateral training group will perform exercises using one limb at a time, whereas the bilateral training group will perform the same exercises simultaneously with both limbs. The control group will receive no structured exercise intervention during the study period but will receive general information regarding the benefits of physical activity.
Assessments will be conducted at baseline and after the 12-week intervention. The primary outcome will be heart rate variability measured using a Polar H10 heart rate sensor and Elite HRV software. Secondary outcomes will include peripheral muscle strength assessed by one-repetition maximum testing, functional capacity assessed using the Six-Minute Walk Test and the Glittre Activities of Daily Living Test, and blood pressure measured using a sphygmomanometer.
The findings of this study are expected to provide evidence regarding the optimal resistance training strategy for improving autonomic function and physical performance in individuals with hypertension, thereby supporting the development of safer and more individualized exercise prescriptions.
Hypertension is one of the leading modifiable risk factors for cardiovascular disease and is strongly associated with autonomic nervous system dysfunction. Increased sympathetic activity and reduced parasympathetic activity contribute to impaired cardiovascular regulation, which can be assessed non-invasively through heart rate variability (HRV). Reduced HRV has been associated with increased cardiovascular morbidity and mortality. In addition to autonomic dysfunction, individuals with hypertension frequently exhibit reduced muscle strength, impaired functional capacity, and limitations in daily physical activities.
Resistance training is widely recommended as a safe and effective non-pharmacological intervention for hypertension because it improves blood pressure control, muscular fitness, and overall physical function. Although both unilateral and bilateral resistance training are commonly prescribed, their physiological effects may differ. Unilateral resistance exercises generally involve a smaller active muscle mass, potentially resulting in lower cardiovascular stress while maintaining local muscular adaptations. In contrast, bilateral resistance exercises recruit a larger muscle mass and may induce greater cardiovascular and hemodynamic responses. Despite these theoretical differences, evidence directly comparing their effects on cardiac autonomic regulation in individuals with hypertension remains limited.
The primary objective of this randomized controlled trial is to compare the effects of unilateral and bilateral resistance training on cardiac autonomic function assessed by HRV in adults with hypertension. Secondary objectives include evaluating changes in peripheral muscle strength, functional capacity, activities of daily living, and blood pressure following a supervised resistance training program.
Adults aged 40 to 75 years with a physician-confirmed diagnosis of hypertension who are able to participate safely in resistance exercise will be recruited from Munzur University and Tunceli State Hospital. After providing written informed consent, eligible participants will be randomly assigned to one of three groups using a computer-generated block randomization procedure with sex stratification:
Unilateral Resistance Training Group Bilateral Resistance Training Group Control Group
Participants allocated to the intervention groups will complete a supervised 12-week resistance training program performed twice weekly. Exercise intensity will be prescribed at 60-70% of one-repetition maximum (1RM). Both intervention groups will perform the same resistance exercises, including leg press, knee extension, leg curl, seated row, and chest press. The unilateral group will perform each exercise separately with the right and left limbs, whereas the bilateral group will perform the exercises simultaneously using both limbs. Each exercise session will consist of 2-3 sets of 8-12 repetitions with at least one minute of rest between sets. Training loads will be progressively increased when participants are able to perform more than 20 repetitions with a perceived exertion below 3 on the Modified Borg Scale.
Participants in the control group will not receive supervised resistance training during the 12-week intervention period but will receive standardized education regarding the health benefits of regular physical activity. Following study completion, participants in the control group will be offered the exercise intervention if the training program is demonstrated to be beneficial.
Outcome assessments will be performed at baseline and after completion of the 12-week intervention. HRV will be measured using a Polar H10 heart rate sensor connected to the Elite HRV application. Measurements will be obtained before exercise, immediately after exercise, and during the recovery period. Time-domain variables, including RMSSD, SDNN, pNN50, and mean RR interval, as well as frequency-domain variables, including total power, LF power, HF power, LF/HF ratio, LF peak frequency, and HF peak frequency, will be analyzed.
Peripheral muscle strength will be evaluated using one-repetition maximum testing for leg press, knee extension, leg curl, seated row, and chest press. Functional capacity will be assessed using the Six-Minute Walk Test (6MWT), while functional performance in activities of daily living will be evaluated using the Glittre Activities of Daily Living Test (Glittre-ADL). Resting and exercise blood pressure will be measured using a validated sphygmomanometer.
The study hypothesis is that unilateral resistance training will produce improvements in HRV, muscle strength, and functional capacity comparable to or greater than bilateral resistance training while imposing lower cardiovascular stress. The findings are expected to provide evidence supporting individualized resistance exercise prescription for individuals with hypertension and contribute to the optimization of exercise-based cardiovascular rehabilitation programs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a supervised unilateral resistance training program twice weekly for 12 weeks. Training intensity will be set at 60-70% of one-repetition maximum (1RM). Exercises will include leg press, knee extension, leg curl, seated row, and chest press, performed separately with the right and left limbs. Each session will consist of 2-3 sets of 8-12 repetitions with at least 1 minute of rest between sets. Training load will be progressively increased according to participants' performance and perceived exertion.
Other: Unilateral Resistance Training
Participants will receive a supervised bilateral resistance training program twice weekly for 12 weeks. Exercise intensity will be prescribed at 60-70% of one-repetition maximum (1RM). The training program will include leg press, knee extension, leg curl, seated row, and chest press performed simultaneously with both limbs. Each exercise will be completed for 2-3 sets of 8-12 repetitions with at least 1 minute of rest between sets. Training intensity will be progressively increased according to participants' performance and perceived exertion.
Other: Bilateral Resistance Training
Participants assigned to the control group will not receive supervised resistance training during the 12-week study period. They will receive standardized education regarding the health benefits of regular physical activity. After study completion, participants will be offered the exercise program if the intervention is shown to be beneficial.
Participants will complete a supervised unilateral resistance training program twice weekly for 12 weeks. Exercise intensity will be prescribed at 60-70% of one-repetition maximum (1RM). Exercises include leg press, knee extension, leg curl, seated row, and chest press performed separately with the right and left limbs. Each session consists of 2-3 sets of 8-12 repetitions with at least 1 minute of rest between sets. Training loads will be progressively increased based on participants' performance and perceived exertion using the Modified Borg Scale.
Participants will complete a supervised bilateral resistance training program twice weekly for 12 weeks. Exercise intensity will be prescribed at 60-70% of one-repetition maximum (1RM). Exercises include leg press, knee extension, leg curl, seated row, and chest press performed simultaneously with both limbs. Each session consists of 2-3 sets of 8-12 repetitions with at least 1 minute of rest between sets. Training loads will be progressively increased according to participants' performance and perceived exertion using the Modified Borg Scale.
Muscle Strength
Muscle strength will be assessed using one-repetition maximum (1RM) testing for leg press, knee extension, leg curl, seated row, and chest press exercises.
Time frame: Baseline and Week 12
Functional Capacity
Functional capacity will be evaluated using the Six-Minute Walk Test (6MWT). Walking distance and physiological responses will be recorded before and after the intervention.
Time frame: Baseline and Week 12
RMSSD
Change in the root mean square of successive differences (RMSSD) measured using heart rate variability analysis. RMSSD is reported in milliseconds (ms). Minimum value: 0 ms. There is no fixed maximum value. Higher values indicate greater parasympathetic activity and improved cardiac autonomic function (better outcome).
Time frame: Baseline and Week 12
SDNN
Change in the standard deviation of normal-to-normal intervals (SDNN) measured using heart rate variability analysis. SDNN is reported in milliseconds (ms). Minimum value: 0 ms. There is no fixed maximum value. Higher values indicate greater overall heart rate variability and improved cardiac autonomic function (better outcome).
Time frame: Baseline and Week 12
pNN50
Change in the percentage of successive normal-to-normal intervals differing by more than 50 ms (pNN50). The outcome is expressed as a percentage (%). Minimum value: 0%. Maximum value: 100%. Higher values indicate greater parasympathetic activity (better outcome).
Time frame: Baseline and Week 12
Mean RR Interval
Change in mean RR interval measured using heart rate variability analysis. The outcome is expressed in milliseconds (ms). Minimum value: 0 ms. There is no fixed maximum value. Higher values generally indicate a lower resting heart rate and improved autonomic regulation (better outcome).
Time frame: Baseline and Week 12
Total Power
Change in total power measured using heart rate variability analysis. The outcome is expressed in milliseconds squared (ms²). Minimum value: 0 ms². There is no fixed maximum value. Higher values indicate greater overall heart rate variability (better outcome).
Time frame: Baseline and Week 12
LF Power
Change in low-frequency (LF) power measured using heart rate variability analysis. The outcome is expressed in milliseconds squared (ms²). Minimum value: 0 ms². There is no fixed maximum value. Higher values generally indicate greater autonomic modulation.
Time frame: Baseline and Week 12
HF Power
Change in high-frequency (HF) power measured using heart rate variability analysis. The outcome is expressed in milliseconds squared (ms²). Minimum value: 0 ms². There is no fixed maximum value. Higher values indicate greater parasympathetic activity (better outcome).
Time frame: Baseline and Week 12
LF Peak
Change in low-frequency peak (LF Peak) measured using heart rate variability analysis. The outcome is expressed in hertz (Hz). Minimum value: 0 Hz. There is no fixed maximum value.
Time frame: Baseline and Week 12
HF Peak
Change in high-frequency peak (HF Peak) measured using heart rate variability analysis. The outcome is expressed in hertz (Hz). Minimum value: 0 Hz. There is no fixed maximum value.
Time frame: Baseline and Week 12
Activities of Daily Living
Change in activities of daily living performance assessed using the Glittre Activities of Daily Living (Glittre ADL) Test. The outcome is the total time required to complete the Glittre ADL Test, measured in seconds (s). Minimum value: 0 seconds. There is no fixed maximum value. Lower completion times indicate better functional performance in activities of daily living (better outcome), whereas higher completion times indicate poorer functional performance (worse outcome).
Time frame: Baseline and Week 12
Blood Pressure
Systolic and diastolic blood pressure will be measured using a validated sphygmomanometer before exercise, immediately after exercise, and 30 minutes after exercise during the baseline and post-intervention assessments.
Time frame: Baseline and Week 12
Plan to share: No
Started Jun 2026 (actual). Primary completion is estimated for Sep 2026, 3 months after the start.
Of 1,405 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 3 months is below that.
Counting every sponsor, half of 1,500 studies reached it within 23 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.